Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks

Stock Research Monitor: TGTX, RARE, and VNDA

LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on TRVN sign up now at www.wallstequities.com/registration. On Monday, July 09, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 7,756.20, up 0.88%; the Dow Jones Industrial Average edged 1.31% higher, to finish at 24,776.59; and the S&P 500 closed at 2,784.17, up 0.88%. This Tuesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), Ultragenyx Pharmaceutical Inc. (NASDAQ: GEO), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

TG Therapeutics

On Monday, shares in New York headquartered TG Therapeutics Inc. recorded a trading volume of 781,717 shares. The stock ended the session 0.36% higher at $14.00. The Company's shares have gained 35.92% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.16% and 18.73%, respectively. Moreover, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the US, have a Relative Strength Index (RSI) of 56.09. Get the full research report on TGTX for free by clicking below at:

www.wallstequities.com/registration/?symbol=TGTX

Trevena

Chesterbrook, Pennsylvania headquartered Trevena Inc.'s stock closed the day flat at $1.49 with a total trading volume of 641,665 shares. The stock is trading below its 50-day moving average by 16.18%. Additionally, shares of Trevena, which develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 32.33. Access the free research report on TRVN now by signing up at:

www.wallstequities.com/registration/?symbol=TRVN

Ultragenyx Pharmaceutical

Shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. recorded a trading volume of 571,844 shares, which was above their three months average volume of 528.69 thousand shares. The stock ended yesterday's trading session 0.53% higher at $82.90. The Company's shares have advanced 63.48% over the previous three months and 29.69% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 18.26% and 50.26%, respectively. Furthermore, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 61.88.

On June 21^st, 2018, research firm Credit Suisse downgraded the Company's stock rating from 'Outperform' to 'Neutral'. Are you already registered with Wall St. Equities? Do so now for free, and get the report on RARE at:

www.wallstequities.com/registration/?symbol=RARE

Vanda Pharmaceuticals

Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc.'s stock finished Monday's session 0.50% lower at $19.90 with a total trading volume of 453,607 shares. The Company's shares have advanced 10.56% in the last month, 29.22% over the previous three months, and 18.45% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 14.25% and 22.43%, respectively. Additionally, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 72.97. Aspiring Member, please take a moment to register below for your free research report on VNDA at:

www.wallstequities.com/registration/?symbol=VNDA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities